請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19197
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 阮雪芬 | |
dc.contributor.author | Yun-Peng Chen | en |
dc.contributor.author | 陳允芃 | zh_TW |
dc.date.accessioned | 2021-06-08T01:48:28Z | - |
dc.date.copyright | 2016-08-24 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-02 | |
dc.identifier.citation | 1. J. M. Maris, Recent advances in neuroblastoma. N Engl J Med 362, 2202-2211 (2010).
2. J. M. Maris, K. K. Matthay, Molecular biology of neuroblastoma. J Clin Oncol 17, 2264-2279 (1999). 3. J. R. Park, R. Bagatell, W. B. London, J. M. Maris, S. L. Cohn, K. K. Mattay, M. Hogarty, C. O. G. N. Committee, Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 60, 985-993 (2013). 4. N. Bown, S. Cotterill, M. Lastowska, S. O'Neill, A. D. Pearson, D. Plantaz, M. Meddeb, G. Danglot, C. Brinkschmidt, H. Christiansen et al., Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340, 1954-1961 (1999). 5. E. F. Attiyeh, W. B. London, Y. P. Mosse, Q. Wang, C. Winter, D. Khazi, P. W. McGrady, R. C. Seeger, A. T. Look, H. Shimada et al., Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353, 2243-2253 (2005). 6. R. C. Seeger, G. M. Brodeur, H. Sather, A. Dalton, S. E. Siegel, K. Y. Wong, D. Hammond, Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313, 1111-1116 (1985). 7. H. Caron, P. van Sluis, J. de Kraker, J. Bokkerink, M. Egeler, G. Laureys, R. Slater, A. Westerveld, P. A. Voute, R. Versteeg, Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 334, 225-230 (1996). 8. P. F. Ambros, I. M. Ambros, G. M. Brodeur, M. Haber, J. Khan, A. Nakagawara, G. Schleiermacher, F. Speleman, R. Spitz, W. B. London et al., International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 100, 1471-1482 (2009). 9. S. Gherardi, E. Valli, D. Erriquez, G. Perini, MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin. Front Oncol 3, 42 (2013). 10. N. Iraci, D. Diolaiti, A. Papa, A. Porro, E. Valli, S. Gherardi, S. Herold, M. Eilers, R. Bernardoni, G. Della Valle et al., A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res 71, 404-412 (2011). 11. M. Huang, W. A. Weiss, Neuroblastoma and MYCN. Cold Spring Harb Perspect Med 3, a014415 (2013). 12. J. H. Kang, P. G. Rychahou, T. A. Ishola, J. Qiao, B. M. Evers, D. H. Chung, MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun 351, 192-197 (2006). 13. R. W. Schnepp, J. M. Maris, Targeting MYCN: a good BET for improving neuroblastoma therapy? Cancer Discov 3, 255-257 (2013). 14. E. Bell, L. Chen, T. Liu, G. M. Marshall, J. Lunec, D. A. Tweddle, MYCN oncoprotein targets and their therapeutic potential. Cancer Lett 293, 144-157 (2010). 15. A. A. Hadjiolov, P. V. Venkov, R. G. Tsanev, Ribonucleic acids fractionation by density-gradient centrifugation and by agar gel electrophoresis: A comparison. Anal Biochem17, 263-267 (1966). 16. R. C. Lee, R. L. Feinbaum, V. Ambros, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854 (1993). 17. B. J. Journal of Clinical OncologyReinhart, F. J. Slack, M. Basson, A. E. Pasquinelli, J. C. Bettinger, A. E. Rougvie, H. R. Horvitz, G. Ruvkun, The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403, 901-906 (2000). 18. M. Sun, W. L. Kraus, Minireview: Long noncoding RNAs: new 'links' between gene expression and cellular outcomes in endocrinology. Mol Endocrinol 27, 1390-1402 (2013). 19. K. W. Vance, C. P. Ponting, Transcriptional regulatory functions of nuclear long noncoding RNAs. Trends Genet 30, 348-355 (2014). 20. K. C. Wang, H. Y. Chang, Molecular mechanisms of long noncoding RNAs. Mol Cell 43, 904-914 (2011). 21. S. Geisler, J. Coller, RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Na Rev Mo Cell Biol. 14, 699-712 (2013). 22. M. Sun, W. L. Kraus, From discovery to function: the expanding roles of long noncoding RNAs in physiology and disease. Endocr Rev 36, 25-64 (2015). 23. M. Cesana, D. Cacchiarelli, I. Legnini, T. Santini, O. Sthandier, M. Chinappi, A. Tramontano, I. Bozzoni, A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 147, 358-369 (2011). 24. G. K. Pandey, C. Kanduri, Long noncoding RNAs and neuroblastoma. Oncotarget 6, 18265-18275 (2015). 25. F. Ferre, A. Colantoni, M. Helmer-Citterich, Revealing protein-lncRNA interaction. Brief Bioinform 17, 106-116 (2016). 26. Q. Lu, S. Ren, M. Lu, Y. Zhang, D. Zhu, X. Zhang, T. Li, Computational prediction of associations between long non-coding RNAs and proteins. BMC Genomics 14, 651 (2013). 27. V. Suresh, L. Liu, D. Adjeroh, X. Zhou, RPI-Pred: predicting ncRNA-protein interaction using sequence and structural information. Nucleic Acids Res 43, 1370-1379 (2015). 28. U. K. Muppirala, V. G. Honavar, D. Dobbs, Predicting RNA-protein interactions using only sequence information. BMC Bioinform. 12, 489 (2011). 29. K. Wang, M. Saito, B. C. Bisikirska, M. J. Alvarez, W. K. Lim, P. Rajbhandari, Q. Shen, I. Nemenman, K. Basso, A. A. Margolin et al., Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol 27, 829-839 (2009). 30. C. L. Hsu, H. Y. Chang, J. Y. Chang, W. M. Hsu, H. C. Huang, H. F. Juan, Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data. Oncotarget (2016). 31. B. Langmead, S. L. Salzberg, Fast gapped-read alignment with Bowtie 2. Nat Methods 9, 357-359 (2012). 32. Y. Zhang, T. Liu, C. A. Meyer, J. Eeckhoute, D. S. Johnson, B. E. Bernstein, C. Nusbaum, R. M. Myers, M. Brown, W. Li et al., Model-based analysis of ChIP-Seq (MACS). Genome Biol 9, R137 (2008). 33. M. K. Goel, P. Khanna, J. Kishore, Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res 1, 274-278 (2010). 34. Z. Lubovac-Pilav, D. M. Borras, E. Ponce, M. C. Louie, Using expression profiling to understand the effects of chronic cadmium exposure on MCF-7 breast cancer cells. PLoS One 8, e84646 (2013). 35. L. Wang, J. Li, H. Zhao, J. Hu, Y. Ping, F. Li, Y. Lan, C. Xu, Y. Xiao, X. Li, Identifying the crosstalk of dysfunctional pathways mediated by lncRNAs in breast cancer subtypes. Mol Biosyst 12, 711-720 (2016). 36. M. Negishi, S. P. Wongpalee, S. Sarkar, J. Park, K. Y. Lee, Y. Shibata, B. J. Reon, R. Abounader, Y. Suzuki, S. Sugano et al., A new lncRNA, APTR, associates with and represses the CDKN1A/p21 promoter by recruiting polycomb proteins. PLoS One 9, e95216 (2014). 37. T. Li, J. Xie, C. Shen, D. Cheng, Y. Shi, Z. Wu, X. Deng, H. Chen, B. Shen, C. Peng et al., Amplification of Long Noncoding RNA ZFAS1 Promotes Metastasis in Hepatocellular Carcinoma. Cancer Res 75, 3181-3191 (2015). 38. H. Yu, Q. Xu, F. Liu, X. Ye, J. Wang, X. Meng, Identification and validation of long noncoding RNA biomarkers in human non-small-cell lung carcinomas. J Thorac Oncol 10, 645-654 (2015). 39. D. D. Li, Z. Q. Fu, Q. Lin, Y. Zhou, Q. B. Zhou, Z. H. Li, L. P. Tan, R. F. Chen, Y. M. Liu, Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. World J Gastroenterol 21, 9348-9357 (2015). 40. M. Tanaka, H. I. Suzuki, J. Shibahara, A. Kunita, T. Isagawa, A. Yoshimi, M. Kurokawa, K. Miyazono, H. Aburatani, S. Ishikawa et al., EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. Oncogene 33, 2454-2463 (2014). 41. S. X. Chen, J. F. Yin, B. C. Lin, H. F. Su, Z. Zheng, C. Y. Xie, Z. H. Fei, Upregulated expression of long noncoding RNA SNHG15 promotes cell proliferation and invasion through regulates MMP2/MMP9 in patients with GC. Tumour Biol 37, 6801-6812 (2016). 42. Z. L. Wang, B. Li, S. R. Piccolo, X. Q. Zhang, J. H. Li, H. Zhou, J. H. Yang, L. H. Qu, Integrative analysis reveals clinical phenotypes and oncogenic potentials of long non-coding RNAs across 15 cancer types. Oncotarget (2016). 43. J.-J. Zhang, J.-T. Chen, K.-H. Yao, L. Hua, C.-Y. Wang, J.-H. Hu, Up-regulated expression of long non-coding RNA ZFAS1 associates with aggressive tumor progression and poor prognosis in gastric cancer patients. Int J Clin Exp Pathol 9, 2059-2063 (2016). 44. C. Wang, D. Z. Hu, J. Z. Liu, Identification of critical TF-miRNA-mRNA regulation loops for colorectal cancer metastasis. Genet Mol Res 14, 5485-5495 (2015). 45. N. Thorenoor, P. Faltejskova-Vychytilova, S. Hombach, J. Mlcochova, M. Kretz, M. Svoboda, O. Slaby, Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. Oncotarget 7, 622-637 (2016). 46. Y. Chen, S. H. Tseng, H. S. Lai, W. J. Chen, Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery 136, 57-66 (2004). 47. Y. Liu, M. Encinas, J. X. Comella, M. Aldea, C. Gallego, Basic helix-loop-helix proteins bind to TrkB and p21(Cip1) promoters linking differentiation and cell cycle arrest in neuroblastoma cells. Mol Cell Biol 24, 2662-2672 (2004). 48. J. Rader, M. R. Russell, L. S. Hart, M. S. Nakazawa, L. T. Belcastro, D. Martinez, Y. Li, E. L. Carpenter, E. F. Attiyeh, S. J. Diskin et al., Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res 19, 6173-6182 (2013). 49. J. Pirngruber, S. A. Johnsen, Induced G1 cell-cycle arrest controls replication-dependent histone mRNA 3' end processing through p21, NPAT and CDK9. Oncogene 29, 2853-2863 (2010). 50. O. M. El-Agnaf, R. Jakes, M. D. Curran, D. Middleton, R. Ingenito, E. Bianchi, A. Pessi, D. Neill, A. Wallace, Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 440, 71-75 (1998). 51. C. C. Matthews, E. L. Feldman, Insulin-like growth factor I rescues SH-SY5Y human neuroblastoma cells from hyperosmotic induced programmed cell death. J Cell Physiol 166, 323-331 (1996). 52. J. Ruffels, M. Griffin, J. M. Dickenson, Activation of ERK1/2, JNK and PKB by hydrogen peroxide in human SH-SY5Y neuroblastoma cells: role of ERK1/2 in H2O2-induced cell death. Eur J Pharmacol 483, 163-173 (2004). 53. S. Gandhi, A. Wood-Kaczmar, Z. Yao, H. Plun-Favreau, E. Deas, K. Klupsch, J. Downward, D. S. Latchman, S. J. Tabrizi, N. W. Wood et al., PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell 33, 627-638 (2009). 54. E. M. Valente, P. M. Abou-Sleiman, V. Caputo, M. M. Muqit, K. Harvey, S. Gispert, Z. Ali, D. Del Turco, A. R. Bentivoglio, D. G. Healy et al., Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160 (2004). 55. D. C. Angeles, B. H. Gan, L. Onstead, Y. Zhao, K. L. Lim, J. Dachsel, H. Melrose, M. Farrer, Z. K. Wszolek, D. W. Dickson et al., Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat 32, 1390-1397 (2011). 56. M. Yu, M. Ohira, Y. Y. Li, H. Niizuma, M. L. Oo, Y. Y. Zhu, T. Ozaki, E. Isogai, Y. Nakamura, T. Koda et al., High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma. Int J Oncol. 34, 931-938 (2009). 57. M. R. Russell, A. Penikis, D. A. Oldridge, J. R. Alvarez-Dominguez, L. McDaniel, M. Diamond, O. Padovan, P. Raman, Y. M. Li, J. S. Wei et al., CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Res. 75, 3155-3166 (2015). 58. A. A. Yarmishyn, A. O. Batagov, J. Z. Tan, G. M. Sundaram, P. Sampath, V. A. Kuznetsov, I. V. Kurochkin, HOXD-AS1 is a novel lncRNA encoded in HOXD cluster and a marker of neuroblastoma progression revealed via integrative analysis of noncoding transcriptome. BMC Genomics 15 Suppl 9, S7 (2014). 59. G. K. Pandey, S. Mitra, S. Subhash, F. Hertwig, M. Kanduri, K. Mishra, S. Fransson, A. Ganeshram, T. Mondal, S. Bandaru et al., The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. Cancer Cell 26, 722-737 (2014). 60. P. Y. Liu, D. Erriquez, G. M. Marshall, A. E. Tee, P. Polly, M. Wong, B. Liu, J. L. Bell, X. D. Zhang, G. Milazzo et al., Effects of a Novel Long Noncoding RNA, lncUSMycN, on N-Myc Expression and Neuroblastoma Progression. J Natl Cancer Inst Monogr 107 (2015). 61. B. Atmadibrata, P. Y. Liu, N. Sokolowski, L. H. Zhang, M. Wong, A. E. Tee, G. M. Marshall, T. Liu, The Novel Long Noncoding RNA linc00467 Promotes Cell Survival but Is Down-Regulated by N-Myc. Plos One 9, e88112 (2014). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19197 | - |
dc.description.abstract | MYCN屬於MYC癌基因家族一員,且擁有轉錄因子的功能。MYCN基因片段的過度放大與神經母細胞瘤預後好壞有很大的關連性。因此了解MYCN的調控機制,對於理解神經母細胞瘤的病理機轉,與發展治療策略有很大的幫助。近年科學家找到了一種不會轉譯出蛋白質的核醣核酸──長鏈非編碼核醣核酸(long non-coding RNA,lncRNA),這種核糖核酸透過表觀遺傳、轉錄或後轉錄調控,來參與許多生物功能。由於MYCN在基因調控網路中,除了會與不同調控因子交互作用外,lncRNA也有可能藉由與MYCN的交互作用,來協助MYCN的調控。然而,MYCN和lncRNA交互作用的機制尚未清楚。在本研究中,我們提出一套計算方法,來預測可能與MYCN交互作用的lncRNA。此方法藉由神經母細胞瘤病患的基因表現資料,利用MINDy (Modulator Inference by Network Dynamics)演算法,來推論lncRNA是否扮演著調節角色(modulator),與分析此資料的存活率,尋找是否lncRNA基因表現會與MYCN基因在病人存活率上,具有協同效果(synergistic effect)。除此之外,我們也藉由lncRNA的序列資料,與MYCN蛋白序列資料,預測是否有直接的交互作用。我們共找到68個lncRNA,不但具有調節角色,也與MYCN基因表現在病人存活率上具有協同效果。從序列分析上,這些lncRNA的確有很高的機率會與MYCN蛋白有直接的交互作用。我們從lncRNA的功能分析中發現,他們會調控影響細胞死亡和細胞周期終止有關的基因,是影響或導致神經母細胞瘤形成或惡化的重要因素。本研究對於MYCN和lncRNA在神經母細胞瘤的作用機制有更進一步的了解,並期望有效的發展出適當的治療方針。 | zh_TW |
dc.description.abstract | Amplification of MYCN is the most important prognostic marker in neuroblastoma, the most common extracranial solid tumor in children. Understanding the MYCN regulatory networks in neuroblastoma can gain insights into not only the mechanisms of neuroblastoma tumorigenesis, but also the development of therapeutic strategy. In recent years, a great number of long non-coding RNAs (lncRNAs) are identified due to the advances in the sequencing techniques, and these lncRNAs participate in various biological processes by functioning as epigenetic, transcriptional, and post-transcriptional regulators. Therefore, the interplay between MYCN and lncRNAs might be crucial mechanisms in neuroblastoma cells. In additional, many studies suggest that lncRNAs offer several advantages as therapeutic targets. In this study, we employed computational approaches to identify 68 candidate lncRNAs as a modulator in MYCN-regulatory networks. These lncRNAs not only interact with MYCN with a high level of confidence but also have the survival synergistic effect which may promote the risk of death. These lncRNAs might regulate genes which involve in cell death and cell cycle arrest. This work provides information about the lncRNAs in MYCN regulations, as well as insights into the mechanism of MYCN-driven tumorigenesis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T01:48:28Z (GMT). No. of bitstreams: 1 ntu-105-R03945028-1.pdf: 3009975 bytes, checksum: bee241dd1670cf18f9cc21e77eba7340 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 口試委員審定書 i
誌謝 ii 中文摘要 iv Abstract v Contents vi List of figures ix List of tables x Chapter 1 Introduction 1 1.1 Neuroblastoma and MYCN 1 1.2 Long non-coding RNAs in regulatory networks 3 1.3 LncRNAs in neuroblastoma 4 1.4 Aims of this thesis 5 Chapter 2 Materials and Methods 6 2.1 Data source and preprocessing 6 2.2 Modulator analysis 6 2.2.1 Modulator inference by network dynamics 6 2.2.2 Evaluation of MYCN targets predicted by MINDy 8 2.3 Modulator mode of action and biological activity 9 2.3.1 Modulator mode of action 9 2.3.2 Biological activity of modulator 9 2.4 Survival synergistic analysis 10 2.5 Prediction based on primary sequences 11 2.5.1 lncPro 11 2.5.2 RPISeq 12 2.6 Function enrichment analysis 12 Chapter 3 Results 14 3.1 Modulator analysis revealing lncRNAs might play as a modulator in MYCN regulatory networks 14 3.2 Modulator mode of action and biological activity 15 3.3 Survival synergistic analysis 15 3.4 Prediction based on primary sequences identify the candidate lncRNAs 16 3.5 Functional enrichment analysis on lncRNAs modulated genes 16 Chapter 4 Discussion 18 4.1 Some of lncRNAs was associated with diseases 18 4.2 MYCN-regulated lncRNAs 20 4.3 The relation of biological activity and survival 20 4.4 lncRNAs interacting with MYCN to regulate genes involved in neuroblastoma tumorigenesis 21 Chapter 5 Conclusion 23 References 24 Figures 30 Tables 49 | |
dc.language.iso | en | |
dc.title | 探討在神經母細胞瘤中長鏈非編碼核糖核酸和MYCN調控網路的交互作用 | zh_TW |
dc.title | Identification of lncRNA-modulated MYCN Regulatory Networks in Neuroblastoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 傅楸善 | |
dc.contributor.oralexamcommittee | 黃宣誠,蔡懷寬,林振慶 | |
dc.subject.keyword | 神經母細胞瘤,lncRNA,MYCN,交互作用,調節角色, | zh_TW |
dc.subject.keyword | Neuroblastoma,lncRNA,MYCN,interaction,modulator, | en |
dc.relation.page | 68 | |
dc.identifier.doi | 10.6342/NTU201601739 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2016-08-02 | |
dc.contributor.author-college | 電機資訊學院 | zh_TW |
dc.contributor.author-dept | 生醫電子與資訊學研究所 | zh_TW |
顯示於系所單位: | 生醫電子與資訊學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 2.94 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。